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GlycolysisViruses such as HIV, HCV, Mayaro and HCMV affect cellular metabolic pathways, including glycolysis. Al-
though some studies have suggested that the inhibition of glycolysis affects HSV-1 replication and that
HSV-1-infected eyes have increased lactate production, the mechanisms by which HSV-1 induces glycolysis
have never been investigated in detail. In this study, we observed an increase in glucose uptake, lactate efﬂux
and ATP content in HSV-1-infected cells. HSV-1 triggered a MOI-dependent increase in the activity of
phosphofructokinase-1 (PFK-1), a key rate-limiting enzyme of the glycolytic pathway. After HSV-1 infection,
we observed increased PFK-1 expression, which increased PFK-1 total activity, and the phosphorylation of
this enzyme at serine residues. HSV-1-induced glycolysis was associated with increased ATP content, and
these events were critical for viral replication. In summary, our results suggest that HSV-1 triggers glycolysis
through a different mechanism than other herpesviruses, such as HCMV. Thus, this study contributes to a bet-
ter understanding of HSV-1 pathogenesis and provides insights into novel targets for antiviral therapy.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Herpes simplex virus type 1 (HSV-1) is a ubiquitous alphaherpes-
virus that enters latency after primary infection of mucosal tissues
[1]. Upon reactivation, HSV-1 can cause several mucocutaneous le-
sions, keratoconjunctivitis and even encephalitis [2]. HSV-1 virions
consist of a large, double-stranded DNA genome packaged in an ico-
sahedral capsid encased by a proteinaceous tegument and a lipidic
envelope composed of various glycoproteins [3]. The HSV-1 replica-
tion cycle is a well-characterized example of virus–host interaction
[4] because it is dependent on a temporal coordination of viral
protein expression that leads to the activation of immediate-early
(IE; α), delayed-early (DE; β) and late (L; γ) viral genes [4]. It has
been proposed that inhibition of any step of the HSV-1 replicative
cycle may block viral replication, although viral resistance canRespiratórios e do Sarampo,
ntemáticas, Instituto Oswaldo
antes), tmoreno@ioc.ﬁocruz.br
l rights reserved.occur [5,6]. The identiﬁcation of novel types of HSV-1-host cell inter-
action could pave the way to identiﬁcation of antiviral targets that
might lead to future therapies.
Studies on changes in cell metabolism by viral infections have be-
come important in the ﬁeld of virology [7–11] and in other patholo-
gies, such as diabetes, metabolic syndrome and cancer [12–17]. The
use of glucose plays a key role in central carbon metabolism in mam-
malian cells. To be transported into the intracellular milieu, glucose
and other carbohydrates use glucose transporters (GLUT) that are
present in the cellular plasma membrane [18,19]. Glucose can be
used for energy production, which may occur in an oxygen-
dependent or -independent fashion. A long list of metabolic processes
is related to glucose metabolism, including glycogen synthesis, gly-
colysis, and the pentose-phosphate pathway, among others. Glycoly-
sis, for instance, leads to the generation of pyruvate/lactate, NADH
and ATP in anaerobic conditions and is the initial step of aerobic res-
piration, in which glucose is oxidized to carbon dioxide [20].
The key rate-limiting regulatory enzyme of the glycolytic pathway is
the protein 6-phosphofructo-1-kinase (PFK-1; phosphofructokinase-1;
ATP: D-fructose-6-phosphate-1-phosphotransferase; EC 2.7.1.11). In
mammals, PFK-1 is a tetrameric enzyme that is composed of three dif-
ferent subunits, C or P, L and M, which may form homo- and hetero-
tetramers [21]. PFK-1 is regulated at the transcriptional/translational
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tose 2,6-bisphosphate, citrate and phosphorylation [22–27]. Hormones
such as insulin, serotonin and epinephrine also control PFK-1 activity
through regulatory phosphorylation at critical amino acid residues
[28–30].
Many viruses can modulate glucose metabolism. Hexose trans-
port is increased in HIV-1-infected cells due to an enhanced expres-
sion of GLUT 1 and 3 transporters [7]. Human cytomegalovirus
(HCMV) activates GLUT 4 expression [31] and glycolytic metabolism
by a CamKK-dependent activation of PFK-1 [32,33]. HIV-1 gp 120 in-
hibits the glycolytic pathway in neuronal cells [8]. It was recently
demonstrated that hepatitis C virus (HCV) inhibits mitochondrial re-
spiratory chain activity, leading to increased HIF-1 levels and, conse-
quently, higher levels of downstream genes such as those coding for
glycolytic enzymes [11]. Similarly, we have shown that Mayaro virus
enhances PFK-1 activity and glycolysis by increasing the levels of
fructose 2,6-bisphosphate in the host cell [10]. Although there is
some evidence that herpes simplex virus can affect glycolysis
[33–35], the mechanisms by which HCMV and HSV-1 trigger glyco-
lytic metabolism are different [33,36]. Thus, we decided to further
investigate the mechanisms of HSV-1-induced glycolysis. We found
that HSV-1 increases PFK-1 activity, glucose uptake, lactate efﬂux
and ATP content. Interestingly, HSV-1-induced enhancement of
PFK-1 activity seems to be a multi-factorial event, requiring phos-
phorylation at serine residues and increased transcription/transla-
tion of PFK-1. Indeed, PFK-1 seems to be critical for HSV-1
replication because knockdown of PFK-1 impairs the HSV-1 life
cycle.
2. Materials and methods
2.1. Cell and virus
African green monkey kidney cells (Vero cells, ATCC) were cul-
tured in Dulbecco's Modiﬁed Eagle's medium (DMEM; GIBCO, Grand
Island, NY) supplemented with 10% fetal bovine serum (FBS;
HyClone, Logan, Utah), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin and incubated at 37 °C in 5% CO2. To prepare virus stocks,
Vero cells were infected with HSV-1 (AR-29 strain) [37] at a multi-
plicity of infection (MOI) of 0.1. Cells were lysed by three cycles of
freezing and thawing 24 h post-infection (p.i.) and centrifuged at
1500×g at 4 °C for 20 min. The supernatant was collected and stored
at −70 °C for further studies [38]. Viral titers were determined by
plaque-forming assays as described previously [39].
2.2. HSV-1 infection
Monolayers of Vero cells (105) in 24-well plates were either
mock- or HSV-1-infected (AR-29 strain) at different MOIs for 1 h at
37 °C. Cells were washed with PBS to remove residual viruses, and
DMEM with 2% FBS was added. After 20 h, cells were lysed, cellular
debris was cleared by centrifugation, and virus titers in the superna-
tant were determined by plaque-forming assays, unless otherwise
mentioned.
2.3. Plaque-forming assays
Monolayers of Vero cells in 6-well plates were exposed to differ-
ent dilutions of the supernatant from yield-reduction assays for 1 h
at 37 °C. Next, cells were washed with PBS, and DMEM containing
5% FBS and 1% methylcellulose (Fluka) (overlay medium) was
added to cells. After 72 h at 37 °C, the monolayers were ﬁxed with
10% formaldehyde in PBS and stained with a 0.1% solution of crystal
violet in 70% methanol, and the virus titers were calculated by scoring
the plaque-forming units (PFU) [40].2.4. Cell viability
To evaluate cell viability after viral infection, Vero cellswere harvested
after each assay and labeled with 0.4% Trypan blue dye. Alternatively,
monolayers of 104 Vero cells in 96-multiwell plates were infected, and
24 h later, 50 μL of a 1-mg/mL solution of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT; Sigma) was dissolved in
DMEM without serum and added to the cell culture. MTT was removed
after 3 h, 50 μL of acid-isopropanol (0.04 N HCl in isopropanol) was
added and the optical density (OD) was read using an automatic plate
reader with a 570-nm test wavelength and a 690-nm reference wave-
length [41,42]. Cell viability assays were performed in replicates (n=3)
for every experiment.
2.5. Glucose uptake and lactate efﬂux
Vero cells were grown in 75 cm2 ﬂasks (∼8×107 cells) and
infected at MOI 5 in glucose-free DMEM (Invitrogen, CA) supplemen-
ted with 5 mM D-[U-13C] glucose. Supernatants of mock- (without
HSV-1) and HSV-1-infected cells were collected at 2, 4, 6, 8, 10, 12,
14, 16 and 20 h p.i. The concentrations of glucose and lactate in
these supernatants were measured by nuclear magnetic resonance
(NMR) spectroscopy as we performed previously [43] with a Bruker
NMR 400 MHz magnet apparatus (Billerica, MA, USA) [44]. We ana-
lyzed these metabolic parameters up to 20 h p.i. because this repre-
sents the period of one complete HSV-1 replicative cycle [45]. For
each measurement of glucose and lactate, positive and negative
(water) controls were included. In addition, the standard spectrum
of 11 μM methanol (considering the natural 13C abundance of 1-mM
methanol to be 1.1%) was used as an internal standard for every mea-
surement to quantify the concentration of glucose and lactate in the
supernatants from the control and infected cells. Control curves of
Vero cells with different concentrations of glucose were also per-
formed to ensure that we were measuring within the linearity of
the assay. The ﬁnal read-out was normalized by the amount of viable
cells at each time point after infection with MOI 5. Calculation of spe-
ciﬁc rates of glucose uptake and lactate efﬂux was performed as pre-
viously described by others taking into account the peculiarities of
Vero cells [46].
2.6. ATP measurement
The levels of ATP in our cells were measured by the luciferin–lu-
ciferase method, as described by Yang et al. [47]. Brieﬂy, Vero cells
were cultured in a six-well plate (3×105 cells per well) and lysed
at 16 h p.i. with boiled water, as this type of lysate seems to give
more reliable results [61]. Lysates from mock- and HSV-1-infected
cells were assayed for levels of ATP in the presence or absence of
5-mM NaF. Standard curves were generated by serial dilutions of
ATP to ensure that all of the data analyzed were within the linearity
of the assay.
2.7. 6-phosphofructo-1-kinase activity
Cell extracts were used to measure PFK-1 activity using a spectro-
photometric assay [48]. Vero cells were infected with HSV-1 and lysed
with buffer A (10 mMK2HPO4, 0.1% Triton X-100, 0.5 mMPMSF) at dif-
ferent times p.i. Next, cell lysates were incubated in assay medium
(50 mM Tris–HCl (pH 7.4), 5 mMMgCl2, 5 mM (NH4)2SO4, 1 mM fruc-
tose 6-P, 0.1 mM ATP, 5 mM NADH, 1.5 U aldolase, 2.5 U triosepho-
sphate isomerase, 4 U α-glycerophosphate dehydrogenase). NADH
oxidation was determined by measuring the decrease in absorbance
at 340 nm.Assayswere also conducted after lysing Vero cellswith buffer
A without 0.1% Triton X-100, but no differences in PFK-1 activity mea-
sured in buffer A with or without detergent were found. Non-linear
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Menten model equation with Sigmaplot 8.0 for Windows.
2.8. Adsorption and penetration assays
To evaluate whether HSV-1 adsorption affects PFK-1 activity, Vero
cells in 6-well plates were infected with HSV-1 at MOI 5 at 4 °C [49].
Next, PFK-1 activity from mock- and HSV-1-infected cells was deter-
mined by spectrophotometric assays, as described above. To investigate
the effects of HSV-1 infection on PFK-1 activity, Vero cells were incubat-
edwith HSV-1 atMOI 5 at 4 °C for 1 h. Next, the temperaturewas raised
to 37 °C for 1 h [49]. Then, PFK-1 activity frommock- andHSV-1-infeced
cells was determined by spectrophotometric assays, as described above.
2.9. Immunoblotting
To investigatewhetherHSV-1 infection alters PFK-1 protein content,
we performed immunoblotting assays, as previously described [49].
Brieﬂy, Vero cells in 25 cm2 culture dishes (1×106/dish) were infected
with HSV-1 at MOI 5. At 16 h p.i., cellular proteins were extracted using
buffer B (0.2% bromophenol blue; 0.5% β-mercaptoethanol; 1 M Tris–
HCl, pH 6.8; 10% SDS; 1% glycerol). A 20 μg aliquot of the extracted pro-
teins was separated by 10% polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membranes. Then, the membranes
were blockedwith 5% bovine albumin, washed and incubatedwith rab-
bit polyclonal anti-PFK-1 or mouse monoclonal anti-β-actin antibodies
(Santa Cruz Biotechnology, CA and Millipore, MA, respectively) for 1 h.
Rabbit primary antibodies against GLUT 1, 3 and 4 (Santa Cruz
Biotechnology) were used to analyze the levels of transporters in
mock- and HIV-1-infected cells. Reactive proteins were detected by an
enhanced chemiluminescence method after incubating with mouse
anti-rabbit or goat anti-mouse immunoglobulin secondary antibody
linked to horseradish peroxidase, depending on the primary antibody
used (Santa Cruz Biotechnology, Inc., Santa Cruz, CA.) [49]. Additionally,
we performed densitometry analysis of the blots using the software
EagleSight (Version 3.21; Stratagene).
2.10. Immunoprecipitation
To investigate possible modiﬁcations on PFK-1, by regulatory
phosphorylations, we isolated PFK-1 from mock- and HSV-1-
infected cells by immunoprecipitation [29]. Brieﬂy, cells were
infected at MOI 5 and lysed with 16 h p.i. with buffer C (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 2 mM Na3VO4, 10 mM
NaF, 0.1 mM PMSF and 1% Triton X-100). Protein concentrations
were determined by Bradford assays [50]. The lysates (500 μg of
total protein) were incubated with 2 μg of rabbit polyclonal anti-
PFK-1 antibody (Santa Cruz Biotechnology) and rocked gently over-
night at 4 °C. Protein A was incubated with this protein-Ab mix for
2 h at 4 °C, and then samples were microcentrifuged for 5 min at
14,000×g. Additional controls with protein A alone were also includ-
ed. Pellets were washed with PBS and mixed twice. Samples were
subsequently microcentrifuged again, at the same conditions de-
scribed above, and the pellets were resuspended in 50 μl of buffer
B. The samples were heated for 2 min at 100 °C and microcentri-
fuged. The supernatants were normalized by protein content, loaded
onto 10% SDS-PAGE gels and subjected to immunoblotting. PVDF
membranes were incubated with anti-PFK-1 or anti-phosphoserine,
-phosphotyrosine or -phosphothreonine PFK-1 antibodies (Santa
Cruz Biotechnology). Membranes were scanned, and densitometry
analysis was performed as described above.
2.11. Puriﬁcation of PFK-1
PFK-1 was puriﬁed to greater than 90% purity from mock- and
HSV-1-infected Vero cells, as described previously [51]. Brieﬂy, cellswere lysed in buffer D (10 mM potassium phosphate, pH 8.0;
30 mM KF and 3 mM EDTA). Lysates were subjected to sequential
steps of centrifugation (10,000×g for 30 min), precipitation with am-
monium sulfate (from saturation of 45% to 58%) and to Bio-gel A
1.5 m ﬁltration (Bio-Rad, Hercules, CA). Peaks of PFK-1 activity were
pooled and assayed with different concentrations of fructose-6-
phosphate. PFK-1 purity was evaluated by SDS-PAGE electrophoresis
followed by silver staining. Protein quantiﬁcation was performed
using the method of Bradford [50].
2.12. RNA extraction, reverse transcription and RT-qPCR
To analyze whether HSV-1 infection alters the RNA levels of the iso-
forms of PFK-1, hexokinase (HK) or lactate dehydrogenase (LDH), we
performed RT-qPCR analysis. Brieﬂy, Vero cells in 25 cm2 dishes
(1×106/dish) were infected with HSV-1 at MOI 5 for 1 h at 37 °C. At
16 h p.i., total cellular RNA was extracted using Qiagen's RNeasy Mini
Kit, according to the manufacturer's instructions (Qiagen, Hilden,
Germany). First strand cDNA synthesis was conducted using 300 ng of
RandomHexamer Primers (Invitrogen, Carlsbad, CA) byMMLV Reverse
Transcriptase (Invitrogen) with 1 μg RNA. Real-time quantiﬁcation was
performed with 1.5 μl cDNA using SYBR Green qPCR master mix (Ap-
plied Biosystems, Foster City, CA) in 25 μl reaction volume on a Applied
Biosystems Prism 7500 Sequence Detection Systemwith 300 nM of the
following primers: PFKMF — 5′-ATTCGGGCTGTGTTCTGG-3′, PFKMR —
5′-TGGCTAGGATTTTGAGGATGG-3′; PFKLF — 5′-GGACAGGAAAGAG-
GAAGTGAC-3′, PFKLR — 5′-CGTAGATGAGGAAGACTTTGGC-3′; PFKPF
— 5′-CATCGACAATGATTTCTGCGG-3′, PFKR— 5′-CCATCACCTCCAGAAC-
GAAG-3′. Primers for HK and LDH have been described by others [11].
The quantiﬁcation of transcripts in mock- and HSV-1-infected cells
was determined using the ΔΔCt method with the control (mock-
infected cells) as the reference sample (calibrator) and β-actin as the
internal control. All reactions were run in duplicate, and at least three
biological replicates were analyzed. We considered a greater than
ﬁve-fold change over the control levels to be signiﬁcant. By serial loga-
rithmic dilutions, we determined that the efﬁciency of our reactions
was near 100% (0.988).
2.13. Glycolysis inhibition
To investigate whether inhibition of glycolysis affects HSV-1 repli-
cation, Vero cells were infected with HSV-1 at MOI 5 and treated with
the enolase inhibitor NaF at 5 mM [52]. This concentration was cho-
sen because it is virtually non-cytotoxic (>99% cell viability) and in-
hibits enolase. At 16 h p.i., cells were lysed for measuring PFK-1
activity, and viral replication was measured 20 h p.i. by plaque-
forming assays with culture supernatants [39].
Alternatively, to address the impact of a speciﬁc glycolytic inhibitor
and to further investigate the participation of the various isoforms of
PFK-1 on HSV-1 replication, we used siRNA targeting the L, M and P sub-
types of PFK-1. The following Stealth siRNAs (Invitrogen) were used to
target the isoforms: L (PFKLSENSE— 5′-CCACGGAGUUCCUGUACAACCU-
GUA-3′, PFKLANTISENSE — 5′-UACAGGUUGUACAGGAACUCCGUG-3′),
M (PFKMSENSE — 5′-GGGAGGUGUACAAGCUUCUAGCQUCA3′, PFKMA-
NTISENSE— 5′-UGAGCUAGAAGCUUGUACACCUCCC-3′), P (PFKPSENSE
— 5′-GAGGAGAUUUCAAGAUGCGGUUCGA-3′, PFKPANTISENSE — 5′-
UCGAACCGCAUCUUGAAAUCUCCUC-3′) or scrambled control (PFKscr-
SENSE— 5′-GAGUAGCUGGGAAGACAAUUGACGA-3′, PFKscrANTISENSE
— 5′-UCGUCAAUUGUCUUCCCAGCUACUC-3′). The siRNAs were mixed
with Lipofectamine 2000® (Invitrogen) and incubated with Vero cells
in 24-well plates, according to the manufacturer's instructions. Then,
24 h after transfection, Vero cells were infected with HSV-1 at MOI 5,
and lactate concentration and virus titers were measured the following
day in the supernatants of the cultures to monitor glycolysis and viral
replication, respectively. In addition, 24 h and 48 h after transfection,
total RNA was extracted, and speciﬁc silencing of each PFK-1 isoform
Table 1
Changes in glucose uptake, lactate efﬂux and PFK-1 activity after HSV-1 infection.
Time points after infection
Before 10 h After 10 h
Metabolic parameter Mock HSV-1 Mock HSV-1
Glucose uptake
(nmol.h−1.10−7 cells)
37.8±2.3 59.4±1.8 39.2±2.1 55.3±3.6
Fold-change in PFK-1
activity (HSV-1/mock)
NA 1.03 NA 2.5
Lactate efﬂux
(nmol.h−1.10−7 cells)
26.46±1.5 30.56±2.8 26.46±1.9 88.48±6.8
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above.
2.14. Statistical analysis
All data presented in this paper represent the means±standard
error of the means (SEM) of at least three independent biological ex-
periments. All statistical analyses were performed using Excel for
Windows, and p values equal to or less than 0.05 were considered sta-
tistically signiﬁcant by Student's t-test.
3. Results
3.1. HSV-1 infection induces glycolysis
Infection with some viruses affects glucose metabolism [7–11,
32,33,53], and HSV-1 infection of the eye increases lactate production
[35]. Therefore, we decided to further investigate the mechanism of
HSV-1-induced activation of glycolysis. We ﬁrst analyzed the effect
of HSV-1 infection on glucose uptake and lactate efﬂux in mock-
and HSV-1-infected cells. We found that glucose consumption from
mock-infected cells was relatively constant over time and that HSV-
1 infection increased glucose disappearance from the supernatant of
virus-infected cells, starting at 4 h p.i. (Fig. 1A and Table 1). Interest-
ingly, glucose uptake in HSV-1-infected cells seems to be modestly in-
tensiﬁed after 10 h p.i., as measured by the decreased glucose
concentration in the supernatant of HSV-1-infected cells (which led
to a more sound statistical signiﬁcance; pb0.01) (Fig. 1A). Moreover,
the increased glucose uptake from the HSV-1-infected cells correlatedFig. 1. HSV-1 infection induces glycolysis. Vero cells were infected with HSV-1 at MOI 5 for 1
cose. At different times post-infection, the supernatants were collected, and glucose (A) or l
lysed at indicated times with buffer B and immunoblotted using anti-GLUT 3 and β-actin ant
to measure ATP content at 16 h p.i. (D). * and # represent p values below 0.05 and 0.01, rewith an increase in the levels of GLUT 3 during the periods of in-
creased glucose uptake (6 h and 16 h p.i.) (Fig. 1C). Of note, GLUT 1
content was not altered in HSV-1-infected cells over time and no
GLUT 4 expression was detected in Vero cells (data not shown).
During glycolysis, a molecule of glucose is metabolized to yield
two molecules of pyruvate and then further reduced to lactate [54].
Thus, we next analyzed the ability of HSV-1 to increase lactate efﬂux.
Indeed, we found that HSV-1 infection increased the concentration of
lactate in the supernatant starting at 10 h p.i. This difference in lactate
efﬂux between HSV-1-infected and mock-infected cells was statisti-
cally signiﬁcant starting at 10 h p.i. and until 20 h p.i. (Fig. 1B and
Table 1). We thus calculated the ratio of lactate efﬂux and glucose up-
take from 10 h to 20 h p.i and found that it was almost 2:1 (Table 1),
suggesting that HSV-1-infected cells become more glycolytic during
the ﬁnal steps of virus replication [45]. Notably, the ratio until 10 h
p.i. revealed slightly higher lactate efﬂux, which could be attributableh at 37 °C and cultured in glucose-free DMEM supplemented with 5 mM D-[U-13C]glu-
actate (B) concentrations were measured by 13C-NMR spectroscopy [43,44]. Cells were
ibodies (C). The monolayers from mock- and HSV-1-infected Vero cells were also lysed
spectively, for comparisons between mock- and HSV-1-infected cells.
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these time points. In summary, our data conﬁrm the previous obser-
vation that HSV-1 infection induces glycolysis [33,34,55,56].
Cellular ATP levels are affected by glycolysis and may regulate gly-
colytic ﬂow [26], and therefore we measured ATP levels from mock-
and HSV-1-infected cells. We found that HSV-1-infected cells had ap-
proximately two-fold higher levels of ATP than control mock-infected
cells (Fig. 1D). This result can be explained by enhanced glycolytic
catabolic ﬂux, leading to increased intracellular ATP content.3.2. HSV-1-induced activation of PFK-1
As we had conﬁrmed that HSV-1 infection induces glycolysis and
considering that another herpesvirus, HCMV, modulates glycolysis by
targeting the enzyme PFK-1 [37] — we next investigated whether
HSV-1 also regulates this key rate-limiting enzyme of glycolysis. Indeed,
we observed a MOI-dependent increase in PFK-1 activity (Figs. 2A and
S1) that correlated with virus growth, with 105 PFU/mL at MOI 1 and
107 PFU/mL at MOI 5. Because the effects of HSV-1 infection on PFK-1
were more pronounced at MOI 5, we conducted all of the other assays
with this MOI. We then analyzed the temporal proﬁle of HSV-1-
induced enhancement of PFK-1 activity. We found that HSV-1 robustly
increased PFK-1 activity at 16 h p.i. but only slightly increased it at 2 h
p.i. (Fig. 2B). The increased PFK-1 activity was statistically signiﬁcantly
higher in the infected cells than in the mock-infected cells from 16 h
p.i. until the last time point measured (Fig. 2B). The small increase in
PFK-1 activity at 2 h p.i. overlapped with the initial steps of HSV-1 rep-
lication, whereas the more pronounced activation of PFK-1 at 16 h p.i.
was associated with late events of the viral life cycle [45] and correlates
with late activation of glycolysis (Table 1). The very early steps of theFig. 2. HSV-1-induced activation of PFK-1. Vero cells were infected with HSV-1 at dif-
ferent MOIs and lysed at 16 h p.i. (A). Additionally, these cells were infected at MOI 5
and lysed at different time points after infection (B). The PFK-1 activity in these lysates
(panels A and B) was measured by a coupled assay. * represents a p value below 0.05
for comparisons between mock- and HSV-1-infected cells.HSV-1 life cycle, adsorption and penetration, did not modulate PFK-1
activity (Fig. S2A and B). Thus, we decided to focus on investigating
the late HSV-1-induced activation of PFK-1. Furthermore, because the
late activation of PFK-1 had a greater magnitude than the 2 h p.i. peak,
its impact on cellular metabolism may be more meaningful.3.3. Mechanisms of HSV-1-induced PFK-1 activation
To further analyze HSV-1-mediated activation of PFK-1, we stud-
ied the effects of various fructose-6-phosphate concentrations on
PFK-1 activity [10,51]. We observed a high level of PFK-1 activity
with almost all fructose-6-phosphate concentrations analyzed
(Fig. 3A), and the Michaelis–Menten equation best ﬁt the experimen-
tal data. We observed an approximately six-fold increase in PFK-1
Vmax (Table 2), suggesting that during infection an augment in
PFK-1 content may occur [57]. We indeed observed up-regulated ex-
pression of PFK-1 in HSV-1-infected cells as compared with mock-
infected cells, at both the translational and transcriptional levels
(Fig. 3B and C). This HSV-1-induced PFK-1 expression seems to be
isoform-dependent because only mRNA for subtype L of PFK-1 was
signiﬁcantly increased (Fig. 3C). In parallel, we also analyzed whether
other genes that code for key-regulators of glycolysis, such as hexoki-
nase (HK) and lactate dehydrogenase (LDH), are inﬂuenced by HSV-1
infection. By RT-qPCR, we found a signiﬁcant up-regulation of HK
mRNA in HSV-1-infected cells (Fig. 3C), which reinforces the model
that HSV-1 induces glycolysis by modulating the expression of
genes within this pathway.
It has been reported that phosphorylation at critical residues on
PFK-1 may contribute to its activity [57]. Indeed, we observed higher
levels of serine phosphorylation of PFK-1 in HSV-1-infected cells than
in mock-infected cells (Fig. 3D). We did not observe any difference in
the threonine and tyrosine phosphorylation proﬁles between mock-
and HSV-1-infected cells (Fig. 3D).3.4. Glycolysis inhibition impairs HSV-1 replication and HSV-1-triggered
enhancement in ATP content
Inhibition of glycolysis affects HSV-1 replication even when initial
or late steps of this pathway are blocked (with 2-deoxy-D-glucose or
NaF, respectively) [33,55,56]. As we describe the pivotal role of PFK-1
in HSV-1 replication here, we investigated whether the HSV-1 life
cycle would be impaired when this enzyme, which represents an in-
termediate step of glycolysis, is inhibited. We initially reproduced
the classical experiment [50] with the enolase inhibitor, NaF, and
found that this salt blocked HSV-1 replication and HSV-1-induced lac-
tate efﬂux without causing cytotoxicity (Fig. 4A and B; >99% viability
was observed in the assays).
Next, we investigated whether speciﬁc inhibition of PFK-1 affects
HSV-1 replication. As shown in Fig. 4D, we used siRNAs speciﬁc for
each isoform of PFK-1. Neither the siRNAs nor the transfection system
affected cell viability (>99% cell viability). Only the siRNA speciﬁc for
isoform L of PFK-1 was able to signiﬁcantly inhibit HSV-1 production
(Fig. 4E), suggesting the involvement of the L isoform in the HSV-1-
induced activation of glycolysis and the importance of this pathway
for HSV-1 replication.
As we showed that HSV-1-infected cells have increased ATP con-
tent as compared with mock-infected cells (Fig. 1D) and considering
a possible participation of the glycolysis in producing this molecule
— we also investigated whether the inhibition of glycolysis alters
ATP content in HSV-1-infected cells. Indeed, ATP content of HSV-1-
infected cells returned to the levels observed in mock-infected cells
after NaF treatment (Fig. 4C), suggesting that increased levels of
ATP are important for virus replication and related to HSV-1-
induced glycolysis.
Fig. 3.Mechanisms of PFK-1 activation by HSV-1. Vero cells were infected at MOI 5 and lysed at 16 h p.i. with different buffers. (A) Cells were lysed with buffer D, and lysates were
puriﬁed (>90%) [50]. PFK-1 activity was measured in the presence of different concentrations of fructose-6-phosphate. (B) Cells were lysed with buffer B and immunoblotted using
anti-PFK-1 and β-actin antibodies. Densitometry values (target/reference) of the bands are shown below this panel. (C) Cells were lysed, RNA was extracted, and cDNA was syn-
thesized. The relative expression of different genes was measured by Sybr green with the ΔΔCt method using β-actin as the reference housekeeping gene. (D) Cells were lysed with
buffer C, immunoprecipitated and immunoblotted using anti-PFK-1, -phosphoSer, -phosphoTyr and -phosphoThr antibodies. * represents a p value below 0.05 for comparisons be-
tween mock- and HSV-1-infected cells.
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Glucose utilization may lead to an increase in cellular energy pro-
duction and macromolecule synthesis, which are essential features in
the ﬁght against infections [58,59]. Indeed, several viruses modulate
glucose metabolism and the enzyme PFK-1 [7–11,32,33,53]. Here,
we ﬁrst conﬁrmed the previous ﬁnding that infection with HSV-1 en-
hances glucose uptake and lactate efﬂux and that inhibition of glycol-
ysis impairs HSV-1 replication [33,55,56]. More signiﬁcantly, then, we
demonstrate a strong association between these events and the regu-
lation of PFK-1 by HSV-1 infection. We found that HSV-1 increases the
level of ATP in infected cells and increases both the expression of the L
isoform of PFK-1 and its phosphorylation at serine residues. Our re-
sults, together with other investigations [10,32,33], reinforce that
the induction of a high-glycolytic proﬁle in virus-infected cells
[7,47] is not restricted to those agents that cause cell transformation,
such as Rous sarcoma virus and Kaposi's sarcoma-associated
herpesvirus.Table 2
Kinetic parameters of PFK-1 from HSV-1- and mock-infected cells.
Kinetic parameters Mock HSV-1 p
Km (μM) 0.32±0.08 0.41±0.07 0.061
Vmax (mU PFK-1/cell) 3.80±0.01 23.94±0.82 0.001It is interesting that in HSV-1-infected cells, glucose uptake is en-
hanced early during the viral life cycle, but a more glycolytic proﬁle is
observed only at late time points (Table 1). The enhanced glucose up-
take and glycolysis in HSV-1-infected cells were also observed in
other studies using MRC-5 cells [33], although it was not reproduced
in growth arrested cells [60]. Nevertheless, Vastag et al. [60] also used
Vero cells in their assays and observed an increment in glucose-6-
phosphate and hexose-6-phosphate, which is consistent with in-
creased cellular demand for glucose. Moreover, a signiﬁcant accumu-
lation of fructose-1,6-biphosphate, a hallmark of glycolysis engagement,
was observed with an apparent peak at late time points, by this very
same group using Vero cells [60]. Thus, the differences in timing on in-
creased glucose uptake and glycolysis activation indicate that glucose is
initially being used for other purposes in the infected cells. Since it has
been demonstrated that HSV-1 infection leads to an early accumulation
of phosphorylated deoxynucleosides/deoxynucleotides in Vero and
growth arrested cells [60], glucose carbons could be initially used to gen-
erate the molecules necessary for viral DNA synthesis, which is expected
to occur around 6 h p.i. [45]. Moreover, we found that the late activation
of glycolysis is important for HSV-1 replication because inhibition of this
pathway, and more speciﬁcally PFK-1 knockdown, signiﬁcantly impairs
the viral life cycle.
HSV-1 caused a MOI-dependent increase in PFK-1 activity similar
to that for the Mayaro virus [10] and HCMV [32]. However, the mech-
anism by which this occurs varies across these viruses [10,61]. The
Mayaro virus increases the intracellular levels of the classical PFK-1
BFig. 4. Inhibition of glycolysis attenuates HSV-1 replication. Vero cells were infected at MOI 5 for 1 h at 37 °C and treated with 5 mM NaF. Virus replication was measured 20 h after
infection by plaque-forming assays (A), and lactate concentrations were analyzed in the culture supernatants by 13C-NMR spectroscopy (B). Levels of ATP were also measured in the
cell lysates (C). Vero cells were transfected with speciﬁc siRNAs using Lipofectamine 2000®; after 24 h, these cells were infected with HSV-1 (MOI=5). Levels of mRNAs for each
isoform of PFK-1 (D) and virus replication were measured (E) 16 h post-infection (approximately 40 h post-transfection). Remarkably, siRNA knockdown of PFK-1 isoforms 24 h
after transfection was the same as displayed in panel D (data not shown). * represents a p value below 0.05 for the black bars (A to C), siRNA- versus mock-transfected cells (nil
or Lipofectamine®) (D) and HSV-1-infected cells transfected with siRNA for PFK-1L isoform versus experimental controls (nil, Lipofectamine® or SCR siRNA) (E).
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rus, also activates PFK-1 to enhance the glycolytic ﬂow [32], although
by a different mechanism than HSV-1 [33,55]. In HCMV infection, the
cellular enzyme CamKK activates PFK-1 and glycolysis; however,
HSV-1-induced glycolysis is a CamKK-independent event [33]. We
found that HSV-1 increases both the phosphorylation and expression
of PFK-1, thereby inducing glycolysis in infected cells [22,62]. HSV-1
infection caused increased phosphorylation of speciﬁcally serine res-
idues; this is a novel mechanism of herpesvirus-mediated activation
of PFK-1 [32,33]. In general, phosphorylation of PFK-1 serine residues
increases its activity and decreases its sensitivity to ATP [57,63]. This
could also explain the stimulatory effect of PFK-1 on HSV-1-infected
cells even with high intracellular ATP levels. In parallel, we found
that HSV-1 infection increased the expression of PFK-1 at both the
transcriptional and translational levels, similar to HCMV infection
[32,33]. This HSV-1-mediated increase in PFK-1 synthesis was speciﬁc
to isoform L. Increased expression of this particular PFK-1 isoform has
been positively correlated with tumor malignance and glycolysis in
cells displaying the Warburg effect [17,27]. Thus, our results furtherprove that herpesviruses have a unique impact on cellular metabo-
lism [32,33].
HSV-1 infection dramatically changes the energetic balance in
infected cells. HSV-1 inhibits the tricarboxylic acid cycle (TCA cycle)
[60], impairs F2 subunit synthesis from F0–F1 ATP synthase [64] and
increases levels of ATP. This last event is also observed for HCMV
[65] but it is different for Mayaro and HCV [9–11]. The apparent par-
adox of increased ATP content with decreased TCA activity and oxida-
tive phosphorylation in HSV-1-infected cells also contrasts to what is
observed in physiological conditions, in which an increased demand
for ATP is followed by an increase in its synthesis to avoid signiﬁcant
variations [66]. Thus, a possible explanation for the observed effects
in HSV-1-infected cells would need to take into account both the
early and late events that seem to occur in association with glucose
metabolism described here and elsewhere. Vastag et al. demonstrated
that early during infection the de novo nucleotide biosynthesis is trig-
gered by HSV-1 and is pivotal for virus replication [60]. This phenom-
enon seems to occur independently if cells are under active division
or in a growth arrested state, because even in HSV-1-infected Vero
1205J.L. Abrantes et al. / Biochimica et Biophysica Acta 1822 (2012) 1198–1206cells triphosphorylated deoxynucleotide content is increased at early
time points [60]. In the main model presented by Vastag et al., this
early accumulation of nucleosides/nucleotides is derived from glu-
cose carbons [60]. Thus, potentially, in the different cell types in
which such accumulation of nucleosides/nucleotides occurs, more
adenosine backbones would be generated. Additionally, the late acti-
vation of PFK-1/glycolysis would enhance the ﬂow in which part of
the glucose's energetic potential is transferred to these adenosine
backbones. Indeed, the inhibition of glycolysis by NaF reduces not
only HSV-1 replication but also HSV-1-induced augment in ATP
levels. This suggests that increased levels of ATP are also important
for viral replication.
Finally, some of themetabolic changeswe observed inHSV-1-infected
cell are also found in tumor cells and in other conditions of cellular stress
[21,67,68]. In summary, our ﬁndings suggest that HSV-1 infection stimu-
lates the isoform L of PFK-1 by an original mechanism, promoting a
hypermetabolic state [27,69] with a high-glycolytic phenotype. This
study enhances our understanding of HSV-1 physiopathology and sug-
gests novel targets for antiviral therapy.
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